Study Stopped
Study Lapsed
Computerized Cognitive Training in Epilepsy
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The purpose of this randomized uncontrolled single-site trial is to evaluate the efficacy of two novel computerized cognitive enhancing software packages for improving cognitive and behavioral outcomes in patients with epilepsy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jan 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 22, 2016
CompletedFirst Posted
Study publicly available on registry
April 1, 2016
CompletedStudy Start
First participant enrolled
January 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2018
CompletedJuly 18, 2017
July 1, 2017
6 months
March 22, 2016
July 13, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Total Index Score from the Repeatable Battery for the Assessment of Neurocognitive Status (RBANS)
8 Weeks
Secondary Outcomes (3)
The Everyday Cognition Scale (ECog)
8 Weeks
Perceived cognitive abilities on an index of subjective cognitive abilities (Cognitive Self-Report Questionnaire; CSRQ-25)
8 Weeks
Measure of mood (Geriatric Depression Scale)
8 Weeks
Study Arms (2)
Posit Science
EXPERIMENTALLumosity
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Documented diagnosis of epilepsy based on medical records. The records will be reviewed by the PI and the approved study personnel to confirm that a diagnosis of epilepsy has been made.
- Must own a computer or have access to the internet.
You may not qualify if:
- Full Scale IQ \< 80, as assessed by the WASI-II.
- History of chronic progressive neurologic or neurodegenerative illnesses (e.g., Parkinson's disease, multiple sclerosis, dementia, primary or metastatic malignancy). Patients with headache or migraine are not excluded.
- History of Axis I psychiatric illness with psychotic features. (e.g., schizophrenia). Patients with depression or anxiety (treated or untreated) without psychotic features are not excluded.
- Visual or auditory impairment, which precludes participation in part, or all of the testing.
- English as a first language will not be required, but participants must have either received some of their schooling in English or used English in their work for \>10 years.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
New York University School of Medicine
New York, New York, 10016, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stella Karantzoulis, MD
New York University Medical School
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 22, 2016
First Posted
April 1, 2016
Study Start
January 1, 2017
Primary Completion
July 1, 2017
Study Completion
April 1, 2018
Last Updated
July 18, 2017
Record last verified: 2017-07